NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)

Principal Investigator

Shauna McVorran

Study Number

STUDY02002173

Summary

This study is for patients who have low-risk HER2+ breast cancer. In order to take part in the study, these patients also must have had surgery and received prior chemotherapy and HER2-targeted treatment. The usual treatment for these patients is radiation therapy and more HER2-targeted treatment. People who take part in this study will all receive HER2-targeted treatment. Participants will also be randomly assigned to one of two groups. Half of the participants will be assigned to Group 1 and will receive radiation therapy. The other half of the participants will be assigned to Group 2 and will not receive radiation therapy. Researchers hope to learn if receiving HER2-targeted treatment without radiation therapy is better or worse at stopping the cancer from coming back than the usual treatment.

Phase

III

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms